National Holdings (NHLD) 0.4700 $NHLD
Harvard Apparatus Regenerative Technology, Inc. Announces Pricing of Public Offering of Common Stock and Series B Convertible Preferred Stock
Business Wire - Thu Feb 12, 7:45AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, today announced the pricing of its previously announced underwritten public offering. HART is offering 1,800,000 registered shares of its common stock at a price to the public of $1.75 per share, and 695,857 registered shares of its Series B Convertible Preferred Stock ("Series B"
at a price to the public of $8.75 per share, for expected gross proceeds of approximately $9.2 million. At the option of the investor, the Series B is convertible into five shares of common stock of the Company, and will vote with the common stock on all matters on an as converted basis. The Series B has no preference to the common shares in respect of dividends, voting, liquidation or otherwise. In connection with the offering, HART has also granted the underwriter a 30-day option to purchase up to an additional 270,000 shares of common stock offered in the public offering to cover over-allotments, if any. HART intends to use the net proceeds from the offering primarily for research and development, including funding pre-clinical and clinical trials relating to the HART-Trachea, business development, sales and marketing, capital expenditures, working capital and other general corporate purposes.
HART: 2.92 (+0.34)
VolitionRx Limited Announces Closing of Public Offering of Common Stock
PR Newswire - Thu Feb 12, 7:00AM CST
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced the closing of its public offering of 2,475,000 shares of its common stock, at an offering price of $3.75 per share.
VNRX: 4.15 (+0.15)
Harvard Apparatus Regenerative Technology, Inc. Announces Proposed Public Offering of Common Stock and Series B Convertible Preferred Stock
Business Wire - Wed Feb 11, 3:20PM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, today announced that it is proposing to offer shares of its common stock and Series B Convertible Preferred Stock ("Series B" in an underwritten public offering. At the option of the investor, the Series B is convertible into five shares of common stock of the Company, and will vote with the common stock on all matters on an as converted basis. The Series B has no preference to the common shares in respect of dividends, voting, liquidation or otherwise. HART expects to grant the underwriter a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering to cover over-allotments, if any. HART intends to use the net proceeds from the offering primarily for research and development, including funding pre-clinical and clinical trials relating to the HART-Trachea, business development, sales and marketing, capital expenditures, working capital and other general corporate purposes. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
HART: 2.92 (+0.34)
VolitionRx Limited Prices Public Offering of Common Stock
PR Newswire - Fri Feb 06, 7:00AM CST
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced the pricing of its public offering of 2,475,000 shares of its common stock, at an offering price of $3.75 per share. In addition, VolitionRx has granted the underwriters a 30-day over-allotment option to purchase up to 371,250 additional shares of common stock at the public offering price. All of the shares are being offered by the Company. The shares of VolitionRx are expected to begin trading on the NYSE MKT under the symbol "VNRX" on February 6, 2015.
Bluerock Residential Growth REIT (BRG) Announces Closing of Public Offering of Class A Common Stock and Full Exercise of Underwriters' Option
GlobeNewswire - Tue Jan 20, 3:34PM CST
via PRWEB - The Company received approximately $53.7 million in total net proceeds from the offering after deducting underwriting discounts, commissions, fees and estimated offering expenses payable by the Company. The Company intends to use the net proceeds of the offering to invest in multifamily assets and for other general corporate and working capital purposes, which may include the funding of capital improvements at the Company's properties.
BRG: 13.65 (+0.31)
Bluerock Residential Growth REIT (BRG) Prices Public Offering of Class A Common Stock
GlobeNewswire - Wed Jan 14, 7:56AM CST
via PRWEB - The offering is expected to close on or about January 20, 2015, subject to the satisfaction of customary closing conditions. The Company has granted the underwriters a 30-day option to purchase up to 600,000 additional shares to cover overallotments, if any.
BRG: 13.65 (+0.31)
National Holding Corporation's (NHLD) CEO Robert Fagenson on Q4 Fiscal 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Jan 12, 9:32PM CST
Bluerock Residential Growth REIT (BRG) Announces Public Offering of Class A Common Stock
PRWeb - Mon Jan 12, 8:36PM CST
The Company intends to use the net proceeds of the offering to invest in multifamily assets and for other general corporate and working capital purposes, which may include the funding of capital improvements at the Company's properties.
BRG: 13.65 (+0.31)
InsiderInsights.com Daily Round Up 1/6/15: XOMA, CODI, MNST, BBY
InsiderInsights - at Seeking Alpha - Thu Jan 08, 9:37AM CST
MNST: 117.74 (-1.77), CODI: 16.61 (+0.03), MILL: 2.07 (+0.09), NRX: 6.67 (-0.14), BBY: 39.11 (-0.08), FUND: 7.47 (+0.05), LVS: 60.43 (+1.71), SPB: 94.05 (+0.80), QVCA: 29.47 (+0.42), LMCA: 37.97 (+0.06), BGH: 21.24 (+0.06), SIX: 45.11 (-0.05), AGIO: 118.55 (+0.11), XOMA: 3.41 (-0.01), JGV: 12.93 (+0.09)
National Holdings Corporation Reports Record Financial Results in Fiscal Year 2014
Business Wire - Mon Jan 05, 7:31AM CST
--Plans to Complete 1:10 Reverse Stock Split and Apply for National Stock Exchange Listing in January 2015
Document Security Systems Announces Closing of Public Offering of Common Stock Including Partial Exercise of the Over Allotment Option
PR Newswire - Mon Dec 29, 3:05PM CST
Document Security Systems, Inc. (NYSE MKT: DSS), (DSS), a leader in anti-counterfeiting and authentication solutions, today announced the closing of its previously announced underwritten public offering. A total of 3,715,000 shares of DSS's common stock were sold in the offering at a price to the public of $0.45 per share, resulting in $1.672 million in gross proceeds to DSS. The shares include 415,000 shares of common stock sold pursuant to the underwriters' over-allotment option, which was partially exercised. DSS intends to use the net proceeds from this offering for working capital and other general corporate purposes.
DSS: 0.43 (+0.03)
Document Security Systems Commences Registered Direct Offering of Common Stock
PR Newswire - Mon Dec 22, 3:20PM CST
Document Security Systems, Inc. (NYSE MKT: DSS), (DSS), a leader in anti-counterfeiting and authentication solutions, today announced that it is proposing to offer shares of its common stock in an underwritten public offering. DSS expects to grant the underwriter a 45-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering to cover over-allotments, if any. DSS intends to use the net proceeds from the offering primarily for working capital and other general corporate purposes. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
DSS: 0.43 (+0.03)
National Securities Corporation Expands Equity Research Team with Appointment of Three Research Analysts
Business Wire - Tue Dec 16, 10:00AM CST
--Glenn Williams to Cover Oil & Gas Sector
Immune Pharmaceuticals Inc. Completes Underwriter's Exercise Of Partial Over-Allotment Option
PR Newswire - Wed Nov 26, 3:15PM CST
Immune Pharmaceuticals Inc. (NasdaqCM: IMNP; "Immune" or "the Company" , a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today completed the underwriter's exercise of partial over-allotment option of 459,697 units, at a price of $2.50 per unit, for gross proceeds of approximately $1.06 million, bringing the aggregate gross proceeds of the Company's previously announced underwritten public offering to $9.685 million. The Company received aggregate net proceeds of approximately $8.645 million, after deducting underwriting discounts and commissions and estimated offering expenses. In total, the Company issued 3,909,697 units, with each unit consisting of one share of the Company's common stock, par value $0.0001 per share, and one warrant to purchase 0.25 of a share of the Company's common stock, at an exercise price of $3.75 per a whole share. Separately, $1.0 million recently invested in the Company privately by an existing investor converted into 400,000 units, consisting of 400,000 shares of common stock and warrants to purchase up to 100,000 shares of common stock at the same term as the underwritten public offering, bringing the total gross proceeds raised in November 2014 to $10.685 million.
ICO.VN: 0.035 (unch), IMNP: 1.87 (-0.03)
Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants
PR Newswire - Tue Nov 25, 3:15PM CST
Immune Pharmaceuticals Inc. (NasdaqCM: IMNP; "Immune" or "the Company" , a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today announced the closing of its previously announced underwritten public offering of 3,450,000 units, with each unit consisting of one share of the Company's common stock, par value $0.0001 per share, and one warrant to purchase 0.25 of a share of the Company's common stock, at a price to the public of $2.50 per unit. The warrants will be exercisable for a period of three years following the issuance thereof at an exercise price of $3.75 per a whole share. In connection with the offering, the Company has also granted the underwriter a 30-day option to purchase up to an additional 517,500 units offered in the public offering to cover over-allotments, if any.
ICO.VN: 0.035 (unch), IMNP: 1.87 (-0.03)
Immune Pharmaceuticals Inc. Announces Pricing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock
PR Newswire - Thu Nov 20, 8:00AM CST
Immune Pharmaceuticals Inc. (NASDAQ: IMNP; "Immune" or "the Company" , a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today announced the pricing of its previously announced underwritten, registered public offering. The Company is offering 3,450,000 units, with each unit consisting of one share of the Company's common stock, par value $0.001 per share, and one warrant to purchase 0.25 of a share of the Company's common stock, at a price to the public of $2.50 per unit, for an aggregate gross proceeds of $8,625,000 million. The warrants will be exercisable for a period of three years following the issuance thereof at an exercise price of $3.75 per a whole share. In connection with the offering, the Company has also granted the underwriter a 30-day option to purchase up to an additional 517,500 units offered in the public offering to cover over-allotments, if any. The offering is expected to settle and close on November 25, 2014, subject to the satisfaction or waiver of customary closing conditions.
ICO.VN: 0.035 (unch), IMNP: 1.87 (-0.03)
Immune Pharmaceuticals Inc. Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock
PR Newswire - Wed Nov 19, 3:15PM CST
Immune Pharmaceuticals Inc. (NASDAQ: IMNP; "Immune" or "the Company" , a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today announced that it is proposing to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten, registered public offering. The Company expects to grant the underwriter of the offering an option to purchase additional shares of common stock and warrants to cover over-allotments, if any. The Company intends to use the net proceeds from the offering primarily for general corporate purposes, which may include research and development expenditures, clinical trial expenditures, acquisitions of new technologies, capital expenditures and working capital. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
IMNP: 1.87 (-0.03)
Harvard Apparatus Regenerative Technology, Inc. Announces Pricing of Public Offering of Common Stock and Series B Convertible Preferred Stock
Business Wire - Thu Feb 12, 7:45AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, today announced the pricing of its previously announced underwritten public offering. HART is offering 1,800,000 registered shares of its common stock at a price to the public of $1.75 per share, and 695,857 registered shares of its Series B Convertible Preferred Stock ("Series B"
at a price to the public of $8.75 per share, for expected gross proceeds of approximately $9.2 million. At the option of the investor, the Series B is convertible into five shares of common stock of the Company, and will vote with the common stock on all matters on an as converted basis. The Series B has no preference to the common shares in respect of dividends, voting, liquidation or otherwise. In connection with the offering, HART has also granted the underwriter a 30-day option to purchase up to an additional 270,000 shares of common stock offered in the public offering to cover over-allotments, if any. HART intends to use the net proceeds from the offering primarily for research and development, including funding pre-clinical and clinical trials relating to the HART-Trachea, business development, sales and marketing, capital expenditures, working capital and other general corporate purposes. HART: 2.92 (+0.34)
VolitionRx Limited Announces Closing of Public Offering of Common Stock
PR Newswire - Thu Feb 12, 7:00AM CST
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced the closing of its public offering of 2,475,000 shares of its common stock, at an offering price of $3.75 per share.
VNRX: 4.15 (+0.15)
Harvard Apparatus Regenerative Technology, Inc. Announces Proposed Public Offering of Common Stock and Series B Convertible Preferred Stock
Business Wire - Wed Feb 11, 3:20PM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, today announced that it is proposing to offer shares of its common stock and Series B Convertible Preferred Stock ("Series B"
in an underwritten public offering. At the option of the investor, the Series B is convertible into five shares of common stock of the Company, and will vote with the common stock on all matters on an as converted basis. The Series B has no preference to the common shares in respect of dividends, voting, liquidation or otherwise. HART expects to grant the underwriter a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering to cover over-allotments, if any. HART intends to use the net proceeds from the offering primarily for research and development, including funding pre-clinical and clinical trials relating to the HART-Trachea, business development, sales and marketing, capital expenditures, working capital and other general corporate purposes. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. HART: 2.92 (+0.34)
VolitionRx Limited Prices Public Offering of Common Stock
PR Newswire - Fri Feb 06, 7:00AM CST
VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced the pricing of its public offering of 2,475,000 shares of its common stock, at an offering price of $3.75 per share. In addition, VolitionRx has granted the underwriters a 30-day over-allotment option to purchase up to 371,250 additional shares of common stock at the public offering price. All of the shares are being offered by the Company. The shares of VolitionRx are expected to begin trading on the NYSE MKT under the symbol "VNRX" on February 6, 2015.
Bluerock Residential Growth REIT (BRG) Announces Closing of Public Offering of Class A Common Stock and Full Exercise of Underwriters' Option
GlobeNewswire - Tue Jan 20, 3:34PM CST
via PRWEB - The Company received approximately $53.7 million in total net proceeds from the offering after deducting underwriting discounts, commissions, fees and estimated offering expenses payable by the Company. The Company intends to use the net proceeds of the offering to invest in multifamily assets and for other general corporate and working capital purposes, which may include the funding of capital improvements at the Company's properties.
BRG: 13.65 (+0.31)
Bluerock Residential Growth REIT (BRG) Prices Public Offering of Class A Common Stock
GlobeNewswire - Wed Jan 14, 7:56AM CST
via PRWEB - The offering is expected to close on or about January 20, 2015, subject to the satisfaction of customary closing conditions. The Company has granted the underwriters a 30-day option to purchase up to 600,000 additional shares to cover overallotments, if any.
BRG: 13.65 (+0.31)
National Holding Corporation's (NHLD) CEO Robert Fagenson on Q4 Fiscal 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Jan 12, 9:32PM CST
Bluerock Residential Growth REIT (BRG) Announces Public Offering of Class A Common Stock
PRWeb - Mon Jan 12, 8:36PM CST
The Company intends to use the net proceeds of the offering to invest in multifamily assets and for other general corporate and working capital purposes, which may include the funding of capital improvements at the Company's properties.
BRG: 13.65 (+0.31)
InsiderInsights.com Daily Round Up 1/6/15: XOMA, CODI, MNST, BBY
InsiderInsights - at Seeking Alpha - Thu Jan 08, 9:37AM CST
MNST: 117.74 (-1.77), CODI: 16.61 (+0.03), MILL: 2.07 (+0.09), NRX: 6.67 (-0.14), BBY: 39.11 (-0.08), FUND: 7.47 (+0.05), LVS: 60.43 (+1.71), SPB: 94.05 (+0.80), QVCA: 29.47 (+0.42), LMCA: 37.97 (+0.06), BGH: 21.24 (+0.06), SIX: 45.11 (-0.05), AGIO: 118.55 (+0.11), XOMA: 3.41 (-0.01), JGV: 12.93 (+0.09)
National Holdings Corporation Reports Record Financial Results in Fiscal Year 2014
Business Wire - Mon Jan 05, 7:31AM CST
--Plans to Complete 1:10 Reverse Stock Split and Apply for National Stock Exchange Listing in January 2015
Document Security Systems Announces Closing of Public Offering of Common Stock Including Partial Exercise of the Over Allotment Option
PR Newswire - Mon Dec 29, 3:05PM CST
Document Security Systems, Inc. (NYSE MKT: DSS), (DSS), a leader in anti-counterfeiting and authentication solutions, today announced the closing of its previously announced underwritten public offering. A total of 3,715,000 shares of DSS's common stock were sold in the offering at a price to the public of $0.45 per share, resulting in $1.672 million in gross proceeds to DSS. The shares include 415,000 shares of common stock sold pursuant to the underwriters' over-allotment option, which was partially exercised. DSS intends to use the net proceeds from this offering for working capital and other general corporate purposes.
DSS: 0.43 (+0.03)
Document Security Systems Commences Registered Direct Offering of Common Stock
PR Newswire - Mon Dec 22, 3:20PM CST
Document Security Systems, Inc. (NYSE MKT: DSS), (DSS), a leader in anti-counterfeiting and authentication solutions, today announced that it is proposing to offer shares of its common stock in an underwritten public offering. DSS expects to grant the underwriter a 45-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering to cover over-allotments, if any. DSS intends to use the net proceeds from the offering primarily for working capital and other general corporate purposes. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
DSS: 0.43 (+0.03)
National Securities Corporation Expands Equity Research Team with Appointment of Three Research Analysts
Business Wire - Tue Dec 16, 10:00AM CST
--Glenn Williams to Cover Oil & Gas Sector
Immune Pharmaceuticals Inc. Completes Underwriter's Exercise Of Partial Over-Allotment Option
PR Newswire - Wed Nov 26, 3:15PM CST
Immune Pharmaceuticals Inc. (NasdaqCM: IMNP; "Immune" or "the Company"
, a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today completed the underwriter's exercise of partial over-allotment option of 459,697 units, at a price of $2.50 per unit, for gross proceeds of approximately $1.06 million, bringing the aggregate gross proceeds of the Company's previously announced underwritten public offering to $9.685 million. The Company received aggregate net proceeds of approximately $8.645 million, after deducting underwriting discounts and commissions and estimated offering expenses. In total, the Company issued 3,909,697 units, with each unit consisting of one share of the Company's common stock, par value $0.0001 per share, and one warrant to purchase 0.25 of a share of the Company's common stock, at an exercise price of $3.75 per a whole share. Separately, $1.0 million recently invested in the Company privately by an existing investor converted into 400,000 units, consisting of 400,000 shares of common stock and warrants to purchase up to 100,000 shares of common stock at the same term as the underwritten public offering, bringing the total gross proceeds raised in November 2014 to $10.685 million. ICO.VN: 0.035 (unch), IMNP: 1.87 (-0.03)
Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants
PR Newswire - Tue Nov 25, 3:15PM CST
Immune Pharmaceuticals Inc. (NasdaqCM: IMNP; "Immune" or "the Company"
, a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today announced the closing of its previously announced underwritten public offering of 3,450,000 units, with each unit consisting of one share of the Company's common stock, par value $0.0001 per share, and one warrant to purchase 0.25 of a share of the Company's common stock, at a price to the public of $2.50 per unit. The warrants will be exercisable for a period of three years following the issuance thereof at an exercise price of $3.75 per a whole share. In connection with the offering, the Company has also granted the underwriter a 30-day option to purchase up to an additional 517,500 units offered in the public offering to cover over-allotments, if any. ICO.VN: 0.035 (unch), IMNP: 1.87 (-0.03)
Immune Pharmaceuticals Inc. Announces Pricing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock
PR Newswire - Thu Nov 20, 8:00AM CST
Immune Pharmaceuticals Inc. (NASDAQ: IMNP; "Immune" or "the Company"
, a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today announced the pricing of its previously announced underwritten, registered public offering. The Company is offering 3,450,000 units, with each unit consisting of one share of the Company's common stock, par value $0.001 per share, and one warrant to purchase 0.25 of a share of the Company's common stock, at a price to the public of $2.50 per unit, for an aggregate gross proceeds of $8,625,000 million. The warrants will be exercisable for a period of three years following the issuance thereof at an exercise price of $3.75 per a whole share. In connection with the offering, the Company has also granted the underwriter a 30-day option to purchase up to an additional 517,500 units offered in the public offering to cover over-allotments, if any. The offering is expected to settle and close on November 25, 2014, subject to the satisfaction or waiver of customary closing conditions. ICO.VN: 0.035 (unch), IMNP: 1.87 (-0.03)
Immune Pharmaceuticals Inc. Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock
PR Newswire - Wed Nov 19, 3:15PM CST
Immune Pharmaceuticals Inc. (NASDAQ: IMNP; "Immune" or "the Company"
, a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today announced that it is proposing to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten, registered public offering. The Company expects to grant the underwriter of the offering an option to purchase additional shares of common stock and warrants to cover over-allotments, if any. The Company intends to use the net proceeds from the offering primarily for general corporate purposes, which may include research and development expenditures, clinical trial expenditures, acquisitions of new technologies, capital expenditures and working capital. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. IMNP: 1.87 (-0.03)
